Nasdaq · Healthcare

Tango Therapeutics, Inc. (TNGX)

As-reported financials and recent SEC filings for Tango Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$62.4M

Net income

$-101.6M

Net margin

—

Diluted EPS

$-0.87

ROE

-29.3%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$62.4M	$42.1M	$36.5M	$24.9M	$37.0M
Gross profit	—	—	—	—	—
Operating income	$-111.3M	$-145.6M	$-114.2M	$-111.1M	$-58.2M
Net income	$-101.6M	$-130.3M	$-101.7M	$-108.2M	$-58.2M
Diluted EPS	$-0.87	$-1.19	$-1.08	$-1.23	$-0.94

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-02

42026-06-23

32026-06-23

8-K2026-06-23

1442026-06-17

1442026-06-11

1442026-06-10

8-K2026-06-10

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TNGX

Search Tango Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.